Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTC923 (Sepiapterin) in Phenylketonuria
NCT05166161Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Feb 2022
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of sepiapterin in phenylketonuria (PKU), sponsored by PTC Therapeutics, Inc.. Started Feb 2022; status: completed.
02
Drugs
sepiapterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT05166161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05166161.